How many institutions held ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in Q2 2021?

128 institutional investors reported ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value for Q2 2021. Use the holders table for investor-level position and value details.

Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)

Q: What does CUSIP 00461U105 represent in this 13F holders report?

CUSIP 00461U105 is the security identifier for ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value used to aggregate holder disclosures.

CUSIP: 00461U105

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class: Equity / Common Stock, $0.00001 par value
Shares outstanding: 140,909,091
Total 13F shares: 56,004,936
Share change: +10,561,143
Total reported value: $983,410,407
Put/Call ratio: 74%
Price per share: $17.56
Number of holders: 128
Value change: +$20,628,850
Number of buys: 81
Number of sells: 49

Quarterly Holders Quick Answers

What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2021
Previous quarter: Q1 2021

Recent filing periods for CUSIP 00461U105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Dorsey Wright & Associates	13F	Company	0%	6,110	$153,972,000	—	31 Mar 2021	13F
VR Adviser, LLC	13F	Company	2.6%	3,720,582	$93,759,000	—	31 Mar 2021	13F
Rock Springs Capital Management LP	13F	Company	2.5%	3,569,192	$89,944,000	—	31 Mar 2021	13F
Foresite Capital Management IV, LLC	13F	Company	2.4%	3,399,034	$85,656,000	—	31 Mar 2021	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	2.3%	3,200,000	$80,640,000	—	31 Mar 2021	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	2.1%	2,986,478	$75,259,000	—	31 Mar 2021	13F
VANGUARD GROUP INC	13F	Company	1.5%	2,117,852	$53,370,000	—	31 Mar 2021	13F
Cormorant Asset Management, LP	13F	Company	1.4%	2,000,000	$50,400,000	—	31 Mar 2021	13F
Foresite Capital Management III, LLC	13F	Company	1.4%	1,954,904	$49,264,000	—	31 Mar 2021	13F
Parkman Healthcare Partners LLC	13F	Company	1.2%	1,709,136	$43,070,000	—	31 Mar 2021	13F
Vivo Capital, LLC	13F	Company	1.2%	1,647,214	$41,510,000	—	31 Mar 2021	13F
FMR LLC	13F	Company	1.1%	1,500,974	$37,825,000	—	31 Mar 2021	13F
CITADEL ADVISORS LLC	13F	Company	0.94%	1,327,349	$33,449,000	—	31 Mar 2021	13F
Foresite Capital Management V, LLC	13F	Company	0.89%	1,258,243	$31,708,000	—	31 Mar 2021	13F
Commodore Capital LP	13F	Company	0.73%	1,028,084	$25,908,000	—	31 Mar 2021	13F
Samsara BioCapital, LLC	13F	Company	0.73%	1,022,612	$25,770,000	—	31 Mar 2021	13F
BlackRock Finance, Inc.	13F	Company	0.7%	984,876	$24,819,000	—	31 Mar 2021	13F
Invesco Ltd.	13F	Company	0.64%	907,034	$22,857,000	—	31 Mar 2021	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.59%	831,329	$20,950,000	—	31 Mar 2021	13F
FRAZIER MANAGEMENT LLC	13F	Company	0.49%	696,000	$17,539,000	—	31 Mar 2021	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.46%	650,000	$16,380,000	—	31 Mar 2021	13F
Aisling Capital Management LP	13F	Company	0.45%	634,455	$15,988,000	—	31 Mar 2021	13F
Ghost Tree Capital, LLC	13F	Company	0.43%	600,000	$15,120,000	—	31 Mar 2021	13F
Holocene Advisors, LP	13F	Company	0.37%	525,863	$13,252,000	—	31 Mar 2021	13F
Endurant Capital Management LP	13F	Company	0.32%	455,385	$11,476,000	—	31 Mar 2021	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.32%	447,635	$11,280,000	—	31 Mar 2021	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.27%	376,864	$9,496,000	—	31 Mar 2021	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.26%	367,392	$9,258,000	—	31 Mar 2021	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.24%	343,247	$8,650,000	—	31 Mar 2021	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.24%	336,737	$8,486,000	—	31 Mar 2021	13F
Point72 Asset Management, L.P.	13F	Company	0.23%	327,800	$8,261,000	—	31 Mar 2021	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.23%	317,730	$8,007,000	—	31 Mar 2021	13F
Stenham Asset Management Ltd	13F	Company	0.2%	283,500	$7,144,000	—	31 Mar 2021	13F
DEUTSCHE BANK AG\	13F	Company	0.18%	258,711	$6,520,000	—	31 Mar 2021	13F
NOMURA HOLDINGS INC	13F	Company	0.17%	240,233	$6,047,000	—	31 Mar 2021	13F
Affinity Asset Advisors, LLC	13F	Company	0.16%	222,267	$5,601,000	—	31 Mar 2021	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.15%	214,300	$5,400,000	—	31 Mar 2021	13F
Informed Momentum Co LLC	13F	Company	0.15%	205,295	$5,173,000	—	31 Mar 2021	13F
STATE STREET CORP	13F	Company	0.14%	192,942	$4,862,000	—	31 Mar 2021	13F
Ikarian Capital, LLC	13F	Company	0.13%	188,200	$4,742,000	—	31 Mar 2021	13F
PURA VIDA INVESTMENTS, LLC	13F	Company	0.12%	175,799	$4,430,000	—	31 Mar 2021	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.12%	174,076	$4,387,000	—	31 Mar 2021	13F
Tri Locum Partners LP	13F	Company	0.12%	164,199	$4,138,000	—	31 Mar 2021	13F
HRT FINANCIAL LP	13F	Company	0.11%	152,119	$3,833,000	—	31 Mar 2021	13F
J. Goldman & Co LP	13F	Company	0.1%	144,987	$3,654,000	—	31 Mar 2021	13F
ExodusPoint Capital Management, LP	13F	Company	0.1%	140,855	$3,550,000	—	31 Mar 2021	13F
Global IMC LLC	13F	Company	0.09%	121,563	$3,063,000	—	31 Mar 2021	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.09%	120,582	$3,039,000	—	31 Mar 2021	13F
Bank of New York Mellon Corp	13F	Company	0.08%	111,156	$2,801,000	—	31 Mar 2021	13F
NORTHERN TRUST CORP	13F	Company	0.08%	108,795	$2,741,000	—	31 Mar 2021	13F

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q2 2021

As of 30 Jun 2021, Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by 128 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 56,004,936 shares. The largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, VR Adviser, LLC, Rock Springs Capital Management LP, Foresite Capital Management IV, LLC, BlackRock Inc., VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Cormorant Asset Management, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., and Foresite Capital Management III, LLC. This page lists 128 institutional shareholders reporting positions in this security for the Q2 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2021 vs Q1 2021 Across Filers

Q1 2021 holders

Q2 2021 holders

128

Holder diff

Investor	Q1 2021 Shares	Q2 2021 Shares	Share Diff	Share Chg %	Q1 2021 Value $	Q2 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.